Ambasilide

Ambasilide

SCHEMBL246531

Nc1ccc(C(=O)N2C[C@@H]3C[C@@H](CN(Cc4ccccc4)C3)C2)cc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.53
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA7 P36544 1/20 0.50
CHRNA4 P43681 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ambasilide SCHEMBL427931 1.00 HSD11B1 (0.53) HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL10410768 0.89 GPR183 (0.50) HSD11B1ALDH1A1MEN1KMT2ALMNA
SCHEMBL10409232 0.88 MAPK1 (0.55) HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL10410358 0.88 MEN1 (0.53) HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL9521948 0.87 ALDH1A1 (0.50) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL9521802 0.87 SIGMAR1 (0.50) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL9521359 0.87 KMT2A (0.58) HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL9521748 0.85 KDM4E (0.49) HSD11B1KDM4EALDH1A1CA12CA1
SCHEMBL9523517 0.84 ALDH1A1 (0.51) HSD11B1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL10409272 0.84 SIGMAR1 (0.68) MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240099984-A1 A BIODISSOLVABLE FILM FOR LOCALIZED AND EFFICIENT TREATMENT OF VULVODYNIA THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2024-03-28 US claimed
EP-2459227-B1 Prodrugs containing an aromatic amine connected by an amide bond to a carrier ASCENDIS PHARMA AS (DK) 2021-03-17 EP claimed
US-9173953-B2 Prodrugs containing an aromatic amine connected by an amido bond to a linker ASCENDIS PHARMA AS (DK) 2015-11-03 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20120156260-A1 Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker ASCENDIS PHARMA A/S (DK) 2012-06-21 US claimed
EP-1467705-B1 THERAPEUTIC AGENT DELIVERY TAMPON KIMBERLY CLARK CO (US) 2012-06-20 EP claimed
EP-2459227-A1 PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER Ascendis Pharma A/S (DK) 2012-06-06 EP claimed
EP-2414543-A1 GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE Decode Genetics EHF (IS) 2012-02-08 EP claimed
US-20120021989-A1 GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE DECODE GENETICS EHF. (IS) 2012-01-26 US claimed
WO-2011042920-A1 GENETIC VARIANTS INDICATIVE OF VASCULAR CONDITIONS DECODE GENETICS EHF (IS) 2011-04-14 WO claimed
US-20030045829-A1 Therapeutic agent delivery tampon KIMBERLY-CLARK WORLDWIDE, INC. 2003-03-06 US claimed
EP-1086063-A1 NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES Advanced Medicine, Inc. (US) 2001-03-28 EP claimed
EP-1086063-A4 NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES ADVANCED MEDICINE INC (US) 2001-03-28 EP claimed
CN-1263454-A Device and method for treatment of dysmenorrhea UMD INC (US) 2000-08-16 CN claimed
WO-1999064050-A9 NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES ADVANCED MEDICINE INC (US) 2000-04-20 WO claimed
EP-0988009-A1 DEVICE AND METHOD FOR TREATMENT OF DYSMENORRHEA UMD, Inc. (US) 2000-03-29 EP claimed
WO-1999064050-A1 NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES ADVANCED MEDICINE, INC. (US) 1999-12-16 WO claimed
WO-1998056323-A1 DEVICE AND METHOD FOR TREATMENT OF DYSMENORRHEA UMD, INC. (US) 1998-12-17 WO claimed
EP-0701442-A1 NEW USE OF AMBASILIDE KNOLL AG (DE) 1996-03-20 EP claimed
WO-1994028899-A1 NEW USE OF AMBASILIDE KNOLL AKTIENGESELLSCHAFT (DE) 1994-12-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120156260-A1 Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker DAO, DNPEP, DDC HSD11B1 3157/4885CHRNB2 3048/4885CHRNB4 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.